Drugs / Serine
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07178613 | Nov 2025 → Feb 2026 overdue | colorectal cancer | The First Affiliated Hospital of Xinxiang Medical College | Not yet recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04044131 | Dec 2019 → Mar 2021 | Alzheimer disease, Parkinson disease | Istanbul Medipol University Hospital | Completed | No outcome recorded |
| Phase 2 | NCT04330326 | Jul 2019 → Jul 2020 | NAFLD1 | ScandiBio Therapeutics AB | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT04573153 | Sep 2020 → May 2022 | COVID-19 | ScandiBio Therapeutics AB | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | serine | “Treatment arm will include dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside + standard therapy (hydroxychloroquine).” NCT04573153 ↗3“Subjects in active treatment will receive dietary supplementation with N-acetylcysteine, L-carnitine tartrate, nicotinamide riboside, and serine, administered as a mixture.” NCT04330326 ↗ “Dietary supplement consisting of serine, L-carnitine tartrate, N-acetylcysteine and nicotinamide riboside.” NCT04044131 ↗ |
| Known as | NAC | “N-acetylcysteine (NAC)” NCT04044131 ↗ |
| Route | Oral | “oral serine administration” NCT07178613 ↗ |